Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Regional, Age, and Sex Patterns of Hepatitis C Virus Infection in Russia: Insights from a 42,000-Participant Serosurvey. / Manuylov, Victor A.; Gushchin, Vladimir A.; Chulanov, Vladimir P. и др.
в: Viruses, Том 17, № 12, 1529, 21.11.2025.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Regional, Age, and Sex Patterns of Hepatitis C Virus Infection in Russia: Insights from a 42,000-Participant Serosurvey
AU - Manuylov, Victor A.
AU - Gushchin, Vladimir A.
AU - Chulanov, Vladimir P.
AU - Isaeva, Olga V.
AU - Kleymenov, Denis A.
AU - Pochtovyi, Andrei A.
AU - Mazunina, Elena P.
AU - Bykonia, Evgeniia N.
AU - Tragira, Irina N.
AU - Simakova, Yana V.
AU - Netesov, Sergey V.
AU - Tkachuk, Artem P.
AU - Semenenko, Tatyana A.
AU - Gintsburg, Alexander L.
AU - Kyuregyan, Karen K.
AU - Mikhailov, Mikhail I.
N1 - Regional, Age, and Sex Patterns of Hepatitis C Virus Infection in Russia: Insights from a 42,000-Participant Serosurvey / V. A. Manuylov, V. A. Gushchin, V. P. Chulanov [et al.] // Viruses. – 2025. – Vol. 17. - No. 12. – DOI 10.3390/v17121529. – EDN XPKHYV. The study of participants from Moscow and the Moscow Region, Saint Petersburg and the Leningrad Region, the Republic of Dagestan, the Novosibirsk Region, and the Khabarovsk Region during the period 2018–2020 was funded by the Ministry of Health of the Russian Federation under the state contract “Monitor-Bio” (No. K-27-FCP/66-4). The participation of V. Manuilov and S. Netesov was supported within the framework of the state assignment for research and development funding at Novosibirsk State University (Project No. FSUS-2025-0012). The participation of V. Chulanov was supported by Ministry of Science and Higher Education of the Russian Federation (Federal scientific and technical program for the development of genetic technologies for 2019–2030: Project No. 075-15-2025-519).
PY - 2025/11/21
Y1 - 2025/11/21
N2 - Identifying population groups at greatest risk of hepatitis C virus (HCV) infection is essential for targeting screening and treatment. We analyzed the seroprevalence of antibodies to HCV (anti-HCV) and HCV RNA in serum samples from 37,291 conditionally healthy volunteers collected between 2018 and 2022, and from 4764 individuals sampled in 2008, totaling 42,055 participants. In 2018–2022, anti-HCV prevalence varied by region, ranging from 1.1 to 1.4% in Belgorod, Moscow, and St. Petersburg to 1.8–2.1% in Dagestan, Tatarstan, Novosibirsk, Tyva, and southern Yakutia, and reaching 3.4–5.2% in Khabarovsk and the Arctic zone of Yakutia. In 2008, prevalence in Moscow, Rostov, Sverdlovsk, Tyva, and Yakutia ranged from 1.7% to 3.3%. A significant decline over time was observed: from a mean of 2.6 ± 0.5% in 2008 to 1.9 ± 0.1% in 2018–2022 (p < 0.01). In recent years, men were more frequently anti-HCV-positive than women (2.5 ± 0.2% vs. 1.5 ± 0.2%, p < 0.01), whereas no sex differences were noted in 2008. The age of a sharp prevalence increase shifted from the 20–29 cohort in 2008 to the 30–39 cohort in 2018–2022. Based on the demographic structure, we estimate ~3.23 million anti-HCV carriers in Russia. HCV RNA was detectable in only one-third of seropositive individuals, identifying them as candidates for antiviral therapy. Thus, in contemporary Russia, men aged over 30 years have the highest risk of HCV infection and should be prioritized for targeted screening.
AB - Identifying population groups at greatest risk of hepatitis C virus (HCV) infection is essential for targeting screening and treatment. We analyzed the seroprevalence of antibodies to HCV (anti-HCV) and HCV RNA in serum samples from 37,291 conditionally healthy volunteers collected between 2018 and 2022, and from 4764 individuals sampled in 2008, totaling 42,055 participants. In 2018–2022, anti-HCV prevalence varied by region, ranging from 1.1 to 1.4% in Belgorod, Moscow, and St. Petersburg to 1.8–2.1% in Dagestan, Tatarstan, Novosibirsk, Tyva, and southern Yakutia, and reaching 3.4–5.2% in Khabarovsk and the Arctic zone of Yakutia. In 2008, prevalence in Moscow, Rostov, Sverdlovsk, Tyva, and Yakutia ranged from 1.7% to 3.3%. A significant decline over time was observed: from a mean of 2.6 ± 0.5% in 2008 to 1.9 ± 0.1% in 2018–2022 (p < 0.01). In recent years, men were more frequently anti-HCV-positive than women (2.5 ± 0.2% vs. 1.5 ± 0.2%, p < 0.01), whereas no sex differences were noted in 2008. The age of a sharp prevalence increase shifted from the 20–29 cohort in 2008 to the 30–39 cohort in 2018–2022. Based on the demographic structure, we estimate ~3.23 million anti-HCV carriers in Russia. HCV RNA was detectable in only one-third of seropositive individuals, identifying them as candidates for antiviral therapy. Thus, in contemporary Russia, men aged over 30 years have the highest risk of HCV infection and should be prioritized for targeted screening.
KW - HCV RNA
KW - HCV prevalence
KW - Russian Federation
KW - anti-HCV
KW - conditionally healthy population
KW - hepatitis C virus
UR - https://www.scopus.com/pages/publications/105025931588
UR - https://elibrary.ru/item.asp?id=85125973
UR - https://www.mendeley.com/catalogue/72358282-5c1d-3b7e-b434-0db2ec4337cd/
U2 - 10.3390/v17121529
DO - 10.3390/v17121529
M3 - Article
C2 - 41472200
VL - 17
JO - Viruses
JF - Viruses
SN - 1999-4915
IS - 12
M1 - 1529
ER -
ID: 74604982